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Background: Anthroposophic treatment for attention deficit hyperactivity disorder (ADHD) 
includes special artistic and physical therapies and special medications.
Methods: We studied 61 consecutive children starting anthroposophic treatment for ADHD 
symptoms under routine outpatient conditions. Primary outcome was FBB-HKS (a parents’ 
questionnaire for ADHD core symptoms, 0–3), and secondary outcomes were disease and 
symptom scores (physicians’ and parents’ assessment, 0–10) and quality of life (KINDL® total 
score, 0–100).
Results: A total of 67% of patients fulfilled the DSM-IV criteria for ADHD, 15% had an 
exclusion diagnosis such as pervasive developmental disorders, while 18% did not fulfill 
ADHD criteria for another reason. Anthroposophic treatment modalities used were eurythmy 
therapy (in 56% of patients), art therapy (20%), rhythmical massage therapy (8%), and 
medications (51%). From baseline to six-month follow-up, all outcomes improved significantly; 
average improvements were FBB-HKS total score 0.30 points (95% confidence interval 
[CI]: 0.18–0.43; P , 0.001), FBB-HKS inattention 0.36 (95% CI: 0.21–0.50; P , 0.001), 
FBB-HKS hyperactivity 0.29 (95% CI: 0.14–0.44; P , 0.001), FBB-HKS impulsivity 0.22 
(95% CI: 0.03–0.40; P , 0.001), disease score 2.33 (95% CI: 1.84–2.82; P , 0.001), symptom 
score 1.66 (95% CI: 1.17–2.16; P , 0.001), and KINDL 5.37 (95% CI: 2.27–8.47; P = 0.001). 
Improvements were similar in patients not using stimulants (90% of patients at months 0–6) 
and were maintained until last follow-up after 24 months.
Conclusion: Children with ADHD symptoms receiving anthroposophic treatment had   long-term 
improvement of symptoms and quality of life.
Keywords: anthroposophy, attention deficit disorder with hyperactivity, combined modality 
therapy, prospective studies, quality of life
Background
Symptoms of inattention, hyperactivity, and impulsivity are reported in 8%–16% 
of children,1,2 and 5% of all children fulfill the diagnostic criteria for attention 
deficit   hyperactivity disorder (ADHD).3 ADHD can affect self-esteem, social skills, 
  parent–child relationships, and school performance, and is associated with psychiatric 
comorbidity.4–6 In clinical trials, central stimulants and related medications improve 
ADHD symptoms.7 However, up to 30% of children do not respond to or do not tolerate 
stimulants due to adverse effects,8 and less than 10% continue with stimulants after one 
year.9   Psychosocial interventions are less effective than medications but provide modest 
benefits as add-ons.10,11 Up to two-thirds of children with ADHD use complementary 
or alternative therapies,12 sometimes provided by their physicians.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
240
Hamre et al
Anthroposophic medicine (AM) is a complementary 
system of medicine, founded by Rudolf Steiner and Ita 
Wegman.13 AM is provided by specially trained physicians 
in 56 countries worldwide.14 AM extends the conception of 
human physiology beyond cellular and molecular mecha-
nisms to holistic interactions of overriding functional systems 
(downward causality).15 In particular, a complex equilibrium 
exists between two polar systems, ie, the “nerve-sense 
system” (low metabolic rate, mediator of consciousness) 
and the “metabolic-limb system” of the abdominal organs 
and limbs (high metabolic rate, minimal consciousness, 
mediator of voluntary movement).16 This equilibrium can 
be distorted in human disease. For example, the ADHD 
symptom of hyperactivity is seen to reflect a predominance 
of the metabolic-limb system.17 This imbalance is sought to 
be regulated by special AM therapies (eurythmy movement 
exercises, art therapy, rhythmical massage therapy) and 
special AM medications.17–19
Eurythmy (Greek, meaning “harmonious rhythm”) 
therapy is an active exercise therapy involving cognitive, 
emotional, and volitional elements.20 During eurythmy 
therapy sessions, patients are instructed to perform specific 
movements with the hands, feet or whole body. Eurythmy 
movements are related to the sounds of vowels and conso-
nants, to music intervals or to soul gestures, eg, sympathy-
antipathy.21 A eurythmy therapy cycle usually consists 
of 12–15 sessions of 45 minutes each, administered once 
weekly.22 Between therapy sessions the patients perform 
eurythmy movements daily.
In AM art therapy, the patients engage in painting, draw-
ing, clay modeling, music, or speech exercises.16 An AM art 
therapy cycle usually consists of 12 sessions of 45 minutes 
each, administered once weekly.23 In addition to psychologic 
effects (eg, activation, emotive expression, dialogic commu-
nication with the therapist and with the artistic medium),24,25 
AM art therapy can induce physiologic effects, eg, AM 
speech exercises have effects on heart rate rhythmicity and 
cardiorespiratory synchronization which are not induced by 
spontaneous or controlled breathing alone.26,27 Eurythmy 
exercises have similar effects.28
Rhythmical massage therapy was developed from Swed-
ish massage by Ita Wegman, a physician and physiothera-
pist.29 In rhythmical massage therapy, traditional massage 
techniques (effleurage, petrissage, friction, tapotement, 
vibration) are supplemented by gentle lifting and rhythmi-
cally undulating, stroking movements, where the quality 
of grip and emphasis of movement are altered to promote 
specific effects.30 A rhythmical massage therapy cycle usually 
consists of 6–12 sessions administered once or twice weekly, 
each session lasting 20–30 minutes and followed by a rest 
period of at least 20 minutes.31 Most patients can be treated 
with one cycle of art, eurythmy, or massage therapy, while 
prolonged treatment may be necessary for some patients with 
severe or persistent disease.
AM medications are prepared from plants, minerals, 
animals, and from chemically defined substances, and can be 
prepared in concentrated or potentized form. Potentization 
implies a successive dilution, each dilution step involving 
a rhythmical succussion (repeated shaking of liquids) or 
trituration (grinding of solids into lactose monohydrate). For 
example, a D6 potency (also called 6×) has been potentized 
in a 1:10 dilution six times, resulting in a 1:10-6 dilution.32 
Because potencies beyond D23 do not contain any molecules 
of the original substance, effects cannot readily be explained 
by molecular mechanisms. However, a systematic review of 
in vitro studies found biologic effects of potencies $D23 
in nearly three-quarters of the studies and in more than 
  two-thirds of the studies with highest quality.33 All AM medi-
cations are manufactured according to Good   Manufacturing 
Practice and national drug regulations.   Quality standards 
of raw materials and manufacturing methods are described 
in the Anthroposophic Pharmaceutical Codex.32 Toxico-
logically relevant starting materials (eg, belladonna, lead) 
are highly diluted according to the safety requirements of 
European regulations. The available evidence suggests that 
AM medications and therapies are generally well tolerated, 
with infrequent adverse reactions of mostly mild to moder-
ate severity.34,35
Prior to prescription of AM medications or referral to 
AM therapies, AM physicians have prolonged consultations 
with the patients and their caregivers. These consultations 
are used to take an extended history, to address constitutional 
and psychosocial aspect of the patients’ illness, to explore the 
family’s preparedness to engage in treatment, and to select 
optimal therapy for each patient.16,30
AM therapy providers (physicians, physiotherapists, 
eurythmy therapists, art therapists) are certified following 
structured training programs according to international, 
  standardized curricula. Therapy guidelines exist for   AM med-
ical therapy,36 eurythmy therapy,37 and AM art therapy.23
Related to the AM approach is an educational philosophy 
implemented in more than 3000 Waldorf schools, kinder-
gartens, and curative education centers worldwide, many of 
which provide AM therapies.38,39
AM treatment for children with ADHD symptoms aims at 
general and specific effects. AM art and eurythmy exercises International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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aim to develop concentration, awareness of feelings, and 
motor skills,20,40 whereas rhythmical massage therapy works 
through sensory stimulation. All three therapy modalities (art, 
eurythmy, rhythmical massage) aim at psychologic effects 
from verbal and nonverbal communication with therapists, 
while all AM treatment aims to regulate the equilibrium 
between the nerve-sense system and the metabolic-limb sys-
tem. In addition, AM treatment aims at more specific effects 
on individual ADHD symptoms and constitutional features by 
employing specific art therapy modalities, specific eurythmy 
movements, specific massage techniques, specific massage 
movement patterns, and specific AM medications (further 
descriptions are available17–19,21,29,31). AM medications do 
not contain chemicals with stimulant properties, such as for 
conventional central nervous system sympathomimetics.
AM physicians treating children with ADHD symptoms 
will give information and advice to the family, teachers, and 
other caregivers about the condition, natural history, coping 
and management strategies, and treatment options, and they 
will assess the kindergarten or school situation.17,19,41,42 In 
addition, the physicians will choose among the available AM 
therapy modalities, including a broad range of AM medica-
tions, in order to tailor treatment to the individual needs of 
the patient. Similar to recent guideline recommendations,41,42 
stimulants are not used as initial therapy for moderate ADHD. 
In severe or nonresponsive ADHD, however, AM therapies 
are often combined with stimulants.19 In this respect, there 
has been some debate among AM physicians as to the degree 
of severity necessitating stimulant therapy.43–45
Two small single-center studies have evaluated AM 
painting/drawing/clay therapy46 and eurythmy therapy20 for 
ADHD. We present here a preplanned subgroup analysis of 
children with ADHD symptoms from a multicenter study of 
a broader range of AM therapy options (all artistic therapy 
modalities, eurythmy therapy, rhythmical massage, and 
medications).47
For complementary therapy systems in widespread use, 
regardless of whether evidence from randomized trials exists, 
it has been argued that the conventional drug research strat-
egy, starting with studies of biologic mechanisms and moving 
through Phase I, II, and III clinical trials, is not optimal.48 
Another more appropriate strategy has been proposed, mov-
ing from descriptive studies (Phase I) towards comparative 
studies of the whole system and its parts, and ending with 
studies of biologic mechanisms (Phase V).48 In the context of 
this reversed strategy, the present analysis addressed topics in 
the Phases I and II (therapy paradigms, therapy use, clinical 
outcomes, perceived benefit, and safety).
Methods
study design
This was a prospective, observational, two-year, cohort 
study in a routine outpatient medical setting. The study was 
part of a research project on the effectiveness, costs, and 
safety of AM therapies in outpatients with chronic disease 
(Anthroposophic Medicine Outcomes Study [AMOS]).47,49 
The AMOS project was initiated by a health insurance 
company in conjunction with a health benefit program. The 
present preplanned subgroup analysis concerned a subgroup 
of children with ADHD symptoms. Since only limited data 
on AM treatment for this indication were available,20,46 the 
primary objective was to describe the AM therapy for ADHD 
symptoms (spectrum of AM therapy modalities used, extent 
of combination with conventional therapy) as well as the 
clinical outcome under AM treatment in routine outpatient 
settings. Further research questions addressed adverse reac-
tions and therapy satisfaction.
setting, participants, and therapy
All physicians certified by the Physicians’ Association for 
Anthroposophical Medicine in Germany and working in 
an office-based practice or outpatient clinic were invited to 
participate in the AMOS study. Certification as an AM physi-
cian requires a completed medical degree and a three-year 
structured postgraduate training. The participating physicians 
recruited consecutive patients starting AM therapy under 
routine clinical conditions. AMOS patients were included in 
the present analysis if they fulfilled the eligibility criteria.
Inclusion criteria were: age 3–16 years; enrolment in 
AMOS in the period 01 April 2001 to 31 December 2005 
(the primary outcome of the present analysis was not docu-
mented for AMOS patients enrolled before April 2001); 
ADHD symptoms of at least six months’ duration; starting 
AM therapy for ADHD symptoms: starting AM medical 
treatment (AM-related consultation of at least 15 minutes 
followed by new prescription of AM medication) or referral 
to AM therapy by a nonmedical therapist (art, eurythmy, or 
rhythmical massage).
Patients were excluded if they had previously received the 
AM therapy in question for ADHD symptoms. AM therapy 
was administered at the discretion of the physicians and 
therapists, and evaluated as a whole system50 with subgroup 
analysis of evaluable therapy modality groups. Therapies 
documented in the study were classified as AM therapy 
(consultations with AM physicians, AM art therapy, eurythmy 
therapy, rhythmical massage therapy, AM medications); con-
ventional therapy for ADHD symptoms (central   stimulants, International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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  antidepressants, psychotherapy, occupational therapy, play 
therapy); or other (all other therapies).
clinical assessments
Baseline assessment
Diagnostic criteria for ADHD according to the Diag-
nostic and Statistical Manual of Mental Disorders, 4th 
Edition (DSM-IV) and the International Statistical 
Classification of Diseases and Related Health Problems, 
10th Revision (ICD-10) were assessed using the Diagnostic 
Checklist for Hyperkinetic Disorders/ADHD (DCL-HKS),51 
documented by the physicians. The DCL-HKS (revised 
version DCL-ADHS)52 is a validated checklist for the diag-
nosis of ADHD according to DSM-IV and ICD-10, recom-
mended for clinical assessment of children and adolescents 
with ADHD symptoms in primary care.8,42 The DCL-HKS 
comprises the following items:
•	 A total of 18 core symptoms of ADHD, ie, inattention 
(nine symptoms), hyperactivity (five symptoms), and 
impulsivity (four symptoms)
•	 Additional ADHD criteria according to DSM-IV and 
ICD-10, ie, symptoms beginning before age seven 
years, presence in more than one situation, significant 
impairment in social, academic, or occupational func-
tioning, symptoms not explained by age, developmental 
condition, school strain, very high intelligence, chaotic 
environment, or medication
•	 Exclusion diagnoses for ADHD according to DSM-IV 
or ICD-10, ie, pervasive developmental disorder, 
mood disorder, anxiety disorder, schizophrenia or 
other psychotic disorder, or other relevant psychiatric 
disorder.
These items are combined into an algorithm, resulting 
in the DSM-IV categories: ADHD combined type; ADHD 
predominantly hyperactive-impulsive type; ADHD predomi-
nantly inattentive type; ADHD not otherwise specified; and 
ADHD criteria not fulfilled, as well as in the ICD-10 catego-
ries, ie, F90 hyperkinetic disorder fulfilled/not fulfilled, with 
ICD-10 subtypes.
In addition to DCL-HKS, relevant current and previous 
comorbid disorders were documented in free text. The DCL-
HKS is part of a more comprehensive diagnostic assessment 
system for psychiatric disorders in children and adolescents 
(DISYPS).51,52 DISYPS comprises checklists for the investi-
gation of disorders frequently coexisting with ADHD, such 
as conduct disorder and tics. These checklists were not used 
in the present study.
Primary outcome
The primary outcome was the FBB-HKS (German: 
  Fremdbeurteilungsbogen für Hyperkinetische Störungen) 
at six-month follow-up. The FBB-HKS is a validated 
  questionnaire for core ADHD symptoms according 
to DSM-IV and ICD-10, documented by parents.51,52 
The FBB-HKS consists of 20 items addressing the dimen-
sions of inattention (nine items), hyperactivity (seven items), 
and impulsivity (four items). Each item is rated on a numeric 
rating scale from 0 (“not present”) to 3 (“very strong inten-
sity”). Scores for the three dimensions and a FBB-HKS total 
score are calculated as the average of the respective items 
(range 0–3).
secondary outcomes
Secondary outcomes were disease severity, quality of 
life, satisfaction with therapy, and adverse reactions. 
Disease severity was documented by physicians (disease 
score) and parents (symptom score). Disease score was the 
physician’s global assessment of severity of ADHD symp-
toms using a numeric rating scale53 from 0 (“not present”) 
to 10 (“worst possible”). Symptom score was a compound 
measure of the symptoms for which the parents had sought 
medical attention for their children. At baseline, the parents 
documented one to six symptoms in order of decreasing 
importance and assessed the intensity of each symptom on 
a numeric rating scale from 0 (“not present”) to 10 (“worst 
possible”).53 At each follow-up, the parents documented the 
intensity of the same symptoms which they had documented 
at baseline. Symptom score was the average severity of all 
documented symptoms per patient at each documentation 
point. This score has not been validated.
Quality of life was assessed by the parents of children 
aged 3–7 years and by children aged 8–16 years, using the 
KINDL® questionnaire for measuring health-related quality 
of life in children and adolescents, total quality of life score 
(range 0–100).54
Therapy outcome rating (numeric rating scale 0–10), 
satisfaction with therapy (numeric rating scale 0–10), and 
therapy effectiveness rating (“very effective”, “effective”, 
“less effective”, “ineffective”, or “not evaluable”) were 
documented by parents (effectiveness rating also by 
physicians) after six and 12 months.
Adverse reactions to medications or therapies were docu-
mented by parents after six, 12, 18, and 24 months and by 
the physicians after six months. The documentation included 
suspected cause, intensity (mild/moderate/severe reflecting International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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no/some/complete impairment of normal daily activities, 
respectively), and therapy withdrawal because of adverse 
reactions. Serious adverse events were documented by the 
physicians throughout the study.
Data collection
All data were documented using questionnaires. Question-
naires used at study enrolment were handed out by the 
physicians, and follow-up questionnaires were issued from 
the study office by post. All questionnaires were returned in 
sealed envelopes to the study office. The physicians docu-
mented eligibility criteria, DCL-HKS, and prescription of 
AM therapy at baseline. The therapists documented AM 
therapy administration (the implementation of each therapy 
session was confirmed by signatures of therapists as well as 
parents or patients). All other items were documented by 
parents unless otherwise stated. Parent responses were not 
made available to the physicians. The diagnostic categoriza-
tion of patients with respect to ADHD criteria, based on the 
algorithm in DCL-HKS, was performed in the study office 
and not by the physicians. The physicians were compensated 
60 Euro per included and fully documented patient, while 
the patients received no compensation.
FBB-HKS, symptom score, and KINDL were docu-
mented after 0, 3, 6, 12, 18, and 24 months. Disease score 
was documented after 0 and six months. Medication use 
was documented with name of medication, administration 
frequency (daily, 3–6 days per week, 1–2 days per week, 
1–3 days per month, ,one day per month), and duration 
of use.
The data were entered twice by two different persons 
into Microsoft® Access 97 (Microsoft Corp., Redmond WA). 
The two datasets were compared, and discrepancies were 
resolved by checking with the original data.
Quality assurance, adherence  
to regulations
The study was approved by the Ethics Committee of the 
Faculty of Medicine Charité, Humboldt University, Berlin, 
Germany, and was conducted according to the Declaration of 
Helsinki and largely following the International Conference 
on Harmonisation Guideline for Good Clinical Practice E6. 
Written informed consent was obtained from all patients before 
enrolment. Monitoring visits, including source data verifica-
tion, were performed for all physicians enrolling at least five 
patients into the AMOS study in the recruitment period for the 
present sample (58/61 patients in the present sample).
Data analysis
The data analysis was performed on all patients fulfilling the 
eligibility criteria, using SPSS® 14.0.1 (SPSS Inc., Chicago, 
IL) and StatXact® 5.0.3 (Cytel Software Corporation, Cam-
bridge, MA). The t-test was used for continuous data. The 
McNemar test and Fisher’s exact test were used for binominal 
data. All tests were two-tailed. Missing values for clinical 
outcomes at follow-up assessments were replaced by the last 
value carried forward.
In the main analyses, clinical outcomes were analyzed 
with 0–6 month (primary assessment) and 0–24 month pre-
post comparisons. In an alternative set of analyses, clinical 
outcomes were analyzed with repeated measures analysis 
of variance (ANOVA) testing for within-subject change 
between the time points 0, three and six months, and 0 and 
12, 18, and 24 months, respectively. Results were very similar 
to the pre-post analyses, and are not presented.
Statistical significance was set at P , 0.05. Since this was 
a descriptive study, no adjustment for multiple comparisons 
was performed.55 Pre-post effect sizes were calculated as 
standardized response mean (= mean change score divided 
by the standard deviation of the change score) and classified 
as minimal (,0.20), small (0.20–0.49), medium (0.50–0.79), 
and large ($0.80).56,57
In a preplanned subgroup analysis of the primary out-
come, the sample was restricted to patients not using non-AM 
adjunctive therapies during the first six study months. 
Adjunctive therapies analyzed were medications (Anatomical 
Therapeutic Chemical Classification Index: N06BA centrally 
acting sympathomimetics, N06A antidepressants), psycho-
therapy, occupational therapy, and play therapy. Post hoc 
subgroup analyses were performed on evaluable diagnostic 
groups and AM therapy modality groups.
Results
Participating physicians and therapists
The patients were enrolled by 19 physicians (16 general prac-
titioners and three pediatricians). Comparing these physicians 
with AM-certified general practitioners and pediatricians in 
Germany without study patients (n = 282), no significant dif-
ferences were found regarding gender (47.4% versus 57.1% 
males), age (mean 47.1 ± 6.4 versus 48.1 ± 8.0 years), number 
of years in practice (17.9 ± 7.0 versus 18.9 ± 8.8 years) or 
the proportion of physicians working in primary care (94.7% 
versus 98.6%).
The patients were treated by 30 different AM therapists 
(art, eurythmy, and rhythmical massage). Comparing these International Journal of General Medicine 2010:3
Table 1 sociodemographic data
Item n %
Age groups
  3–5 years 9/61 15
  6–9 years 34/61 56
  10–15 years 16/61 26
  16 years 2/61 3
Living with
  Mother 60/61 98
  Father 38/61 62
  siblings 41/61 71
  Other persons 8/61 13
  More than one person 53/61 87
school type (n = 47 school children)
  state school 21/47 45
  Waldorf school 23/47 49
    school for children with special needs 
(Förderschule)
2/47 4
  Other school 1/47 2
Health insurance coverage
  statutory 55/60 92
  Private 5/60 8
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therapists with certified AM therapists in Germany without 
study patients (n = 1140), no significant differences were 
found regarding gender (76.7% versus 81.1% females), age 
(mean 47.8 ± 7.7 versus 50.3 ± 9.5 years) or the number 
of years since therapist qualification (10.8 ± 6.8 versus 
13.1 ± 8.7 years).
Patient recruitment and follow-up
From 01 April 2001 to 31 December 2005, a total of 
69 patients aged 3–16 years starting AM therapy for ADHD 
symptoms were assessed for eligibility. Of these patients, 61 
fulfilled all eligibility criteria and were included in the analy-
sis. Eight patients were not included because of eligibility 
criteria not being fulfilled (n = 2, because of previous study 
participation [n = 1] and ongoing use of the trial AM therapy 
[n = 1]), patients’ baseline questionnaire missing (n = 5), and 
physician’s baseline questionnaire received longer than two 
months after enrolment (n = 1).
A total of 64% (n = 39/61) of patients were enrolled by 
general practitioners and 36% (n = 22/61) by pediatricians. The 
physicians’ settings were primary care practices (72% of evalu-
able patients, n = 41/57), referral practices (16%, n = 9), and 
outpatient clinics (28%, n = 16). Each physician enrolled 1–2 
patients (n = 12 physicians), 3–5 patients (n = 3), or .5 patients 
(n = 2), with a range of 1–16 patients enrolled per physician. 
The last patient follow-up was on 16 February 2008.
The parents were administered a total of 305 follow-up 
questionnaires, out of which 245 (80.3%) were returned. 
Follow-up rates were 95% (n= 58/61), 87%, 77%, 72%, and 
71% after three, six, 12, 18, and 24 months, respectively. 
At least one follow-up questionnaire was returned in 97% 
(59/61) of patients.
Respondents (n = 47) and nonrespondents (n = 14) in 
the 12-month patient-follow-up did not differ significantly 
regarding age, gender, diagnosis, disease duration, baseline 
FBB-HKS total score, baseline disease score, or base-
line symptom score. A corresponding comparison for the 
six-month follow-up was not performed because of the 
low number of nonrespondents (n = 8). The corresponding 
comparison for the 24-month follow-up showed no significant 
differences regarding age, gender, diagnosis, disease duration, 
or baseline symptom score, while significant differences were 
found for baseline FBB-HKS total score (0.43 points higher 
in nonrespondents than in respondents, 95% confidence 
  interval [CI]: 0.16–0.70; P = 0.002) and baseline disease score 
(1.25 points higher in nonrespondents, 95% CI: 0.44–2.06; 
P = 0.003). The physician six-month follow-up documentation 
was available for 97% (59/61) of patients.
Baseline characteristics
sociodemographic data
The patients were recruited from 11 of 16 German federal 
states. Mean age was 8.9 ± 3.3 years (range 3.4–16.8); a total 
of 84% (51/61) of the patients were boys. Mean household 
size, including the patient, was 3.9 ± 1.2 persons (range 2–8). 
Further sociodemographic data are presented in Table 1.
Disease status
The duration of ADHD symptoms was 6–11 months in 3% 
(n = 2/61) of patients, 1–4 years in 62% (n = 38) and $5 years 
in 34% (n = 21), with a median symptom duration of 3.0 years 
(range 0.5–10.0, mean 3.7 ± 2.0 years).
A total of 67% (n = 41/61) of patients fulfilled the 
DSM-IV criteria for ADHD, 15% (n = 9) had an exclusion 
diagnosis such as pervasive developmental disorders, and 
18% (n = 11) did not fulfill the ADHD criteria for another rea-
son (Table 2). A total of 28% (n = 17/61) of patients fulfilled 
the ICD-10 research criteria for F90 hyperkinetic disorders. 
The FBB-HKS total score at baseline was 1.79 ± 0.47 in 
boys (n = 50), 1.50 ± 0.60 in girls (n = 10), and 1.74 ± 0.50 
in the whole sample.
A current comorbid mental disorder (ICD-10 F00-
F99) was present in 17% (n = 11/61) of patients, with 
F41 anxiety disorders in four patients and seven different 
other diagnoses in seven patients. A current comorbid 
physical diagnosis (not ICD-10 F00-F99) was present 
in 57% (35/61) of patients, with a median of 1.0 (inter-International Journal of General Medicine 2010:3
Table 2 Diagnoses in study participants
ICD-10 Diagnosis n %
DSM-IV criteria for ADHD fulfilled 41 67
F90.0 ADHD, combined type 11
F90.0 ADHD, predominantly hyperactive-impulsive 
type
13
F98.8 ADHD, predominantly inattentive type 11
F90.9 ADHD, not otherwise specified 6
DSM-IV criteria for ADHD not fulfilled
exclusion diagnosis (physicians’ clinical 
diagnosis)
9 15
F84.9 Pervasive developmental disorder, unspecified 4
F81.9 Developmental disorder of scholastic skills, 
unspecified
1
F92.9 Mixed disorder of conduct and emotions 1
Q90.9 Down syndrome, unspecified 1
Q99.2 Fragile X syndrome 1
r27.8 + 
r42
Other and unspecified lack of coordination + 
vertigo not otherwise specified
1
Other reason for nonfulfillment of ADHD 
criteria
11 18
ADHD symptoms beginning after age seven 
years
6
ADHD symptoms not present in more than 
one setting (eg, family, school, medical 
examination)
2
No significant impairment in social, school,  
or work functioning
1
ADHD symptoms explained by age and 
developmental condition or school strain
1
ADHD symptoms explained by very high 
intelligence
1
Total 61 100
Abbreviations: IcD-10, International Statistical Classification of Diseases and Related 
Health  Problems,  10th  Revision;  ADHD,  attention  deficit  hyperactivity  disorder; 
DsM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth edition.
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quartile range [IQR] 0–1, range 0–3) comorbid physical 
diagnoses. The most common comorbid physical diag-
noses were R00-R99 symptoms, signs, and abnormal 
clinical and laboratory findings, not elsewhere classified 
(37%, 19/52 diagnoses), J00-J99 diseases of the respira-
tory system (13%, n = 7), and L00-L99 diseases of the 
skin and subcutaneous tissue (13%, n = 7). According 
to the physician, a mental disorder was suspected in one 
or both parents of 16% (n = 10/61) of patients, while 
familial instability or partner conflicts were suspected 
in 39% (n = 24).
Therapy
Anthroposophic therapies
Patients received AM medical treatment alone (n = 4) or were 
referred to AM art, eurythmy, or rhythmical massage therapy 
without medical treatment (n = 21), or were referred to AM 
therapy with medical treatment (n = 36).
Among patients receiving medical treatment (n = 40), the 
duration of the consultation with the AM physician at study 
enrollment was 15–29 minutes (n = 16 patients), 30–44 minutes 
(n = 9), 45–59 minutes (n = 6), and $60 minutes (n = 9).
Among patients starting medical treatment (n = 40) a 
total of 56 different AM medications were prescribed at 
enrollment. The most frequent medications were Aurum/
Stibium/Hyoscyamus pillules (prescribed to four patients), 
Aurum Comp pillules (n = 3) and Cichorium Plumbo Cultum 
Rh D3 liquid (n = 3). The most frequent starting materials32 
were Aurum naturale (n = 12), Plumbum metallicum (n = 6), 
Cichorium intybus (n = 5), and Bryophyllum = Kalanchoe 
pinnata (n = 4).
Among the 57 patients referred to AM therapy, 89% 
(n = 51) had the planned AM therapy, while for 11% (n = 6) 
the AM therapy documentation is incomplete. AM therapies 
used were eurythmy therapy (n = 34 patients), rhythmical 
massage therapy (n = 5), and art therapy (n = 12) with the 
therapy modalities painting/drawing/clay (n = 2), speech 
exercises (n = 6), and music (n = 4). The AM eurythmy/art/
massage therapy started at a median of six (IQR 2–21) days 
after enrolment. Median therapy duration was 102 days (IQR 
79–203 days), and median number of therapy sessions was 
13 (IQR 11–20). Median number of days between therapy 
sessions was eight days (IQR 6–11 days).
conventional therapies
During the 12 months preceding study enrollment, central 
stimulants had been used by 15% (n = 9/61) of patients. In 
all cases, the stimulant used was methylphenidate (used for 
10–12 months [n = 5], 1–4 months [n = 3], and unknown 
duration [n = 1]). During follow-up, stimulants were used by 
10% (n = 6/61), 16% (n = 10), and 18% (n = 11) of patients 
in months 0–6, 0–12, and 0–24, respectively. In all cases, the 
stimulant used was methylphenidate. All six patients using 
methylphenidate in months 0–6 had used methylphenidate 
in the previous year. Grouping the patients according to 
the year of enrolment, the proportion of methylphenidate 
users in months 0–24 was 25% (n = 2/8), 14% (n = 3/22), 
33% (n = 2/6), 17% (n = 2/12), and 15% (n = 2/13) in years 
2001–2005. This proportion did not change significantly 
during the study (Kruskal–Wallis test, P = 0.823). Mean 
age for users and nonusers of methylphenidate in months 
0–24 was 10.4 and 8.6 years, respectively (mean difference, 
1.9 years, 95% CI: –0.1–3.8 years; P = 0.063). In patients 
with a DSM-IV diagnosis of ADHD (n = 41), the proportion 
of methylphenidate users was 15% (n = 4), 20% (n = 8), and 
22% (n = 9) in months 0–6, 0–12, and 0–24, respectively.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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In the first six study months, 6% (n = 3/61) of all patients 
had psychotherapy, occupational therapy, or play therapy; 
10% (n = 6) used methylphenidate, 0% used antidepressants, 
and 85% (n = 52) used none of these therapies.
Outcomes
clinical outcomes
At six-month follow-up, all clinical outcomes were sig-
nificantly improved from baseline (Table 3, Figures 1–3). 
Standardized response mean effect sizes for the 0–6 month 
comparison were large for disease and symptom scores, 
medium for FBB-HKS total, inattention and hyperactiv-
ity scores, and small for FBB-HKS impulsivity score and 
KINDL (Table 3).
The 0–6 month improvement of the FBB-HKS total 
score was analyzed in evaluable subgroups according to 
diagnosis, therapy, and school type (Table 4). Compared 
with all evaluable patients (mean improvement 0.30 points), 
patients with eurythmy therapy as their main therapy modal-
ity had 7% less improvement (0.30→0.28 points), patients 
fulfilling DSM-IV criteria for ADHD had 20% less improve-
ment (0.30→0.24 points), and patients not using non-AM 
adjunctive therapies (see Methods for further description) 
had 17% more improvement (0.30→35 points). Among 
patients referred for AM art, eurythmy, or rhythmical mas-
sage therapy, the improvement was more pronounced in 
patients also receiving AM medical treatment, compared 
with patients not receiving medical treatment, but the dif-
ference was not significant (mean difference 0.10 points, 
95% CI: –0.16–0.37 points; P = 0.434). Among school-
children, the improvement was similar in those attending 
Waldorf schools (0.31 points) and other schools (0.30). 
The 0–6 months improvement of the FBB-HKS total score 
showed a weak and nonsignificant positive correlation with 
age (Spearman-Rho = 0.24, P = 0.070).
At 24-month follow-up, all analyzed clinical outcomes 
(disease score was not documented beyond six-month 
follow-up) were significantly improved from baseline. Effect 
sizes for the 0–24 month comparison were large for FBB 
total and hyperactivity scores and symptom score, medium 
for FBB-HKS inattention score and KINDL, and small for 
FBB-HKS impulsivity score (Table 5).
Other outcomes
At six-month follow-up, parents’ average therapy outcome rat-
ing (numeric rating scale from 0 “no help at all” to 10 “helped 
very well”) was 6.29 ± 2.70, and parent satisfaction with therapy 
(numeric rating scale from 0 “very dissatisfied” to 10 “very 
satisfied”) was 7.45 ± 2.12. The parents’ effectiveness rating 
of eurythmy, art, or rhythmical massage therapy was positive 
(“very effective” or “effective”) in 68% (n = 34/50) of evaluable 
patients, and negative (“less effective”, “ineffective”, or “not 
evaluable”) in 32% (n = 16). The physicians’ effectiveness rating 
was positive in 84% (49/61) and negative in 16% (n = 9).
From 6- to 12-month follow-up, parent satisfaction with 
therapy decreased by average 1.32 points (95% CI: 0.55–2.10; 
P = 0.001), whereas the parents’ therapy outcome rating and 
the parents’ as well as the physicians’ effectiveness ratings 
did not change significantly.
Adverse reactions
The frequency of reported adverse drug reactions was 10% 
(3/31 users) for AM medications and 36% (4/11 users) for 
methylphenidate (P = 0.064). Adverse drug reactions of 
severe intensity were reported in one patient taking three 
different AM medications. Medication was stopped due to 
reported adverse reactions in two patients (AM medications, 
n = 1 and methylphenidate, n = 1). No adverse reactions from 
other medications or from nonmedication therapies occurred. 
No serious adverse events occurred.
Table 3 clinical outcomes at 0–6 months
Outcome (range) n 0 months 6 months 0–6 months differencea SRM
Mean (SD) Mean (SD) Mean (95% CI) P value
FBB-HKs (0–3)
  Total 60 1.74 (0.50) 1.44 (0.53) 0.30 (0.18 to 0.43) ,0.001 0.63
  Inattention 60 1.87 (0.63) 1.52 (0.58) 0.36 (0.21 to 0.50) ,0.001 0.62
  Hyperactivity 61 1.60 (0.76) 1.31 (0.69) 0.29 (0.14 to 0.44) ,0.001 0.50
  Impulsivity 61 1.73 (0.84) 1.51 (0.83) 0.22 (0.03 to 0.40) ,0.001 0.30
symptom score (0–10) 60 6.51 (1.26) 4.85 (2.11) 1.66 (1.17 to 2.16) ,0.001 0.87
Disease score (0–10) 60 7.07 (1.54) 4.73 (1.74) 2.33 (1.84 to 2.82) ,0.001 1.23
KInDL total quality of life (0–100) 58 63.95 (12.87) 69.32 (9.22) 5.37 (2.27 to 8.47) 0.001 0.46
Note: aPositive differences indicate improvement.
Abbreviations: CI, confidence interval; SD, standard deviation; SRM, standardized response mean effect size (minimal , 0.20; small 0.20–0.49; medium 0.50–0.79; large $ 0.80).International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Discussion
The aim of this two-year prospective cohort study was to 
obtain information on AM therapy for children with ADHD 
symptoms under routine outpatient conditions in Germany. 
Two-thirds of the patients engaged in eurythmy movement 
exercises or artistic therapies, and two-thirds used AM medi-
cations. Patients were treated largely without stimulants (82% 
of patients). Under AM treatment, significant and sustained 
improvements in ADHD symptoms and quality of life were 
observed. AM therapies were well tolerated.
Strengths of this study include a long follow-up period, 
a standardized assessment of ADHD core symptoms as well 
as quality of life, and high representativeness. Patients were 
recruited from more than half of the German federal states, 
91% of those screened and eligible were enrolled, and the 
participating physicians and therapists resembled eligible 
but not participating physicians and therapists with respect 
to demographic characteristics. These features suggest that 
the study mirrors contemporary AM therapy for ADHD 
symptoms in outpatient settings to a high degree.
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Figure 1 FBB-HKs scores.
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Figure 3 KInDL total quality of life score.
Note: range: 0–100, higher scores indicate better quality of life. Age 3–7 years, 
parents’ assessment; age 8–16 years, patients’ assessment (n = 58).
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Figure 2 Disease and symptom scores.
Note: range: 0 “not present”, 10 “worst possible”. Disease score (physicians’ assessment, n = 60). symptom score (parents’ assessment, n = 60).
Because referral for AM treatment for ADHD symptoms 
is not dependent on the fulfillment of diagnostic criteria for 
ADHD,17,19 we included children with ADHD-related diagno-
ses and subsyndromal ADHD symptoms, as well as children 
fulfilling DSM-IV criteria for ADHD. The latter group was ana-
lyzed separately but had a modest sample size of 41 patients. 
Comparisons with other studies of DSM-IV-ADHD should 
therefore be interpreted with some caution. The fulfillment of 
ADHD diagnostic criteria was assessed by a validated checklist 
(DCL-HKS),51,52 and symptom severity was assessed with a 
validated questionnaire recommended for use in primary care 
(FBB-HKS).51,52 However, the physicians and parents did not 
receive special training in ADHD symptom rating. Also, the 
documentation did not include teacher ratings.
This analysis assessed AM as a whole system.50 
  Supplementary subgroup analysis was possible for patients 
referred for eurythmy therapy and similar improvement was 
documented in this group, while the sample size of the other 
therapy modality subgroups (art therapy, rhythmical massage 
therapy, AM medical therapy) did not allow for subgroup 
analysis. The influence of the AM therapy modality and other 
therapy variables (eg, duration of the consultation with the 
physician at study enrolment and number of AM therapy ses-
sions) on clinical outcomes has been assessed in multivariate 
analyses of children in AMOS with ADHD symptoms and 
other chronic indications.49
Because the study had a long recruitment period, the 
study physicians were not able to participate throughout 
the period and to screen and enroll all eligible patients. 
For a different subset of patients from the AMOS project 
(patients referred to AM therapies for any chronic indica-
tion and enrolled before April 1st, 2001), it was estimated 
that physicians enrolled every fourth eligible patient.58 
This selection could bias the results if physicians were 
able to predict therapy response and if they preferentially 
screened and enrolled such patients for whom they expected 
a particularly favorable outcome. In this case, one would 
expect the degree of selection (ie, the proportion of eligible 
versus enrolled patients) to correlate positively with clini-
cal outcomes, measured by the 0–12 month difference in 
symptom score. That was not the case, the correlation was 
almost zero (Spearman-Rho -0.04, P = 0.496, n = 364).58 
Likewise, another analysis of 500 adult patients enrolled 
into AMOS in the period 1999–2005 showed no correlation 
between the degree of selection and the 0–6 month differ-
ence in symptom score (Hamre et al submitted for publica-
tion). These analyses do not suggest that the participating 
physicians’ expectations of future therapy response led to 
any selection bias affecting clinical outcomes.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Selection bias may also occur at the level of participation 
versus nonparticipation of eligible physicians, in that 94% of 
certified AM physicians treating children with ADHD symp-
toms did not enroll patients into the present sample. These 
nonparticipating physicians resembled the participating phy-
sicians with respect to demographics. We cannot, however, 
exclude differences in other aspects, such as the physicians’ 
preferred methods for treatment of ADHD symptoms.
A limitation of the study is the absence of a compari-
son group receiving conventional treatment or no therapy. 
Accordingly, one must consider several other possible causes 
for the observed improvements apart from the AM treatment. 
In order to address possible dropout bias, missing values were 
replaced by the last value carried forward.59 In a subgroup 
analysis of the FBB-HKS total score, the improvement was 
similar in patients not using adjunctive treatment, including 
stimulants. Therefore, adjunctive therapies cannot explain 
the improvement. Dietary modifications12,60 were not docu-
mented in the study and could therefore not be evaluated. 
During a two-year follow-up period, as in this study, some 
natural or developmental recovery of ADHD symptoms may 
occur.61 Regression to the mean due to symptom fluctuation 
with preferential self-selection to therapy and study inclu-
sion at symptom peaks is another possibility. According to 
a previous analysis of mixed diagnoses from the AMOS 
project,59 this phenomenon could explain up to 14% of the 
improvement of disease score. Other possible confounders 
are psychologic factors and nonspecific effects (eg, placebo 
effects, context effects, physician-patient interactions, patient 
expectations, and social desirability effects). However, 
because AM therapy was evaluated as a whole system, the 
question of specific therapy effects versus nonspecific effects 
was not an issue in the present analysis.
The outcome analysis of this study comprised seven 
clinical outcome measures, including six outcomes analyzed 
at two follow-up assessments, ie, a total of 13 analyses 
(Tables 3 and 5). We did not use P value adjustment for mul-
tiple testing, which is a limitation in regard to the risk of find-
Table 4 FBB-HKs total score subgroup analyses 0–6 months
Group  n 0 months 6 months 0–6 month difference
Mean (SD) Mean (SD) Mean (95% CI) P value
Main analysis: Patients with evaluable data at 0 months 60 1.74 (0.50) 1.44 (0.53) 0.30 (0.18–0.43) ,0.001
subgroups according to main therapy modality
1. eurythmy therapy with/without medical treatment 39 1.70 (0.51) 1.42 (0.54) 0.28 (0.12–0.44) 0.001
2.   eurythmy, art or rhythmical massage therapy  
with medical treatment
36 1.74 (0.48) 1.38 (0.50) 0.36 (0.20–0.51) ,0.001
3.   eurythmy, art or rhythmical massage therapy  
without medical treatment
21 1.68 (0.53) 1.43 (0.55) 0.25 (0.01–0.49) 0.042
Other subgroups
4. Waldorf school pupils 23 1.72 (0.49) 1.40 (0.46) 0.31 (0.14–0.48) 0.001
5. Pupils of other schools 37 1.75 (0.52) 1.45 (0.58) 0.30 (0.12–0.47) 0.002
6. DSM-IV criteria for ADHD fulfilled 40 1.76 (0.47) 1.52 (0.53) 0.24 (0.09–0.39) 0.002
7.   Patients not using stimulants,  
psychotherapy, occupational 
therapy, or play therapy in months 0–6
44 1.69 (0.52) 1.34 (0.52) 0.35 (0.20–0.50) ,0.001
8. criteria 6 + 7 27 1.70 (0.49) 1.38 (0.53) 0.32 (0.14–0.50) 0.001
Abbreviations: ADHD, attention deficit hyperactivity disorder; CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition;   
sD, standard deviation.
Table 5 clinical outcomes at 0–24 months
Outcome (range) n 0 months 24 months 0–24 month differencea SRM
Mean (SD) Mean (SD) Mean (95% CI) P value
FBB-HKs (0–3)
  Total 60 1.74 (0.50) 1.28 (0.61) 0.45 (0.31 to 0.59) ,0.001 0.84
  Inattention 60 1.87 (0.63) 1.43 (0.60) 0.44 (0.27 to 0.61) ,0.001 0.65
  Hyperactivity 61 1.60 (0.76) 1.07 (0.71) 0.53 (0.36 to 0.69) ,0.001 0.80
  Impulsivity 61 1.73 (0.84) 1.36 (0.91) 0.37 (0.17 to 0.56) ,0.001 0.48
symptom score (0–10) 60 6.51 (1.26) 4.41 (2.24) 2.09 (1.56 to 2.62) ,0.001 1.02
KInDL total quality of life (0–100) 58 63.95 (12.87) 70.71 (10.99) 6.75 (3.51 to 10.00) ,0.001 0.55
Note: aPositive differences indicate improvement.
Abbreviations: CI, confidence interval; SD, standard deviation; SRM, standardized response mean effect size (minimal , 0.20; small 0.20–0.49; medium 0.50–0.79; large $ 0.80).International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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ing significant results by chance (Type I error). However, the 
problem of multiple testing has no universal solution, because 
P value adjustment will increase the risk of Type II errors.55 
The P values in this study indicated significant improvements, 
with P values # 0.001 in all analyses, a constellation that 
would not be expected to occur by chance (eg, a Bonferroni 
adjustment for 13 tests would have indicated P , 0.004 as 
the significance level).
Apart from two studies with five20 and 17 patients,46 
respectively, this study provides the first data on the treatment 
of ADHD symptoms in AM settings. The higher prevalence 
of ADHD according to DSM-IV versus ICD-10 criteria (67% 
versus 28% of patients), as well as the overrepresentation of 
boys (84%), are in accordance with the literature.3,8,62 Mental 
comorbidity was less frequent in our study (17% of patients) 
than elsewhere (up to two-thirds),8 but an underestimation 
in our study cannot be excluded, because the documentation 
did not include a structured assessment of conduct disorders, 
learning disorders, and tics. Forty-four percent of patients in 
our study were assessed in specialist practice or in outpatient 
clinics. Similarly, in a large German administrative database, 
36% of children and adolescents with a claims diagnosis of 
ICD-10 F90 hyperkinetic disorder had seen a specialist at 
least once during the past year.63 Study documentation did 
not include data on parental education and occupational 
levels, nor household income, but the proportion of privately 
insured patients (8%) was similar to that of the German 
population (10%).64
Baseline severity of ADHD symptoms, assessed by the 
FBB-HKS total score, was two standard deviations worse 
than average score values in German children aged 4–17 
years.52 Symptom severity in our sample was higher in boys 
than in girls, which is similar to that in the general popula-
tion.52 Quality of life at baseline assessed by KINDL total 
score was one standard deviation worse than average score 
values in German children aged 3–17 years, and approxi-
mately equal to the score of children classified as abnormal 
according to the Strengths and Difficulties Questionnaire.65 
The proportion of patients treated with stimulant medication 
(16% of all patients and 20% of those with a DSM-IV diagno-
sis of ADHD in months 0–12) would seem to be lower than 
in Germany at the start of this study. In a large administra-
tive dataset from the German Federal State of Hesse in year 
2001, stimulants were prescribed to 25% of children aged 
3–15 years with a claims diagnosis of ICD-10 F90 hyper-
kinetic disorder.66 This comparison should be treated with 
some caution, because the database analysis did not include 
factors influencing stimulant prescription, such as ADHD 
diagnostic criteria, symptom severity, and comorbidity. Dur-
ing the study period, the prescription of methylphenidate in 
Germany was almost tripled (2001→2007: 16→46 million 
defined daily doses),67 an increase which was not reflected 
in our study. Possibly, families with children engaging in 
eurythmy or artistic exercises or other AM therapies might 
be less motivated to use stimulants.
In this study AM therapy was followed by improvement 
of ADHD symptoms and quality of life. This confirms 
previous findings.20,46 Symptom improvement in the first 
six months of this study, assessed by parents, amounted to 
one-half to two-third standard deviations for the FBB-HKS 
scores, which is similar to six-month results following other 
(non-AM) nonmedication therapies for ADHD.68,69 The 
corresponding improvement of symptom score was more 
pronounced, amounting to 1.3 standard deviations. Possible 
reasons for this discrepancy are differing scale construc-
tions and constructs of the two instruments. The FBB-HKS 
(0–3 points) measures a broad range of ADHD symptoms, 
while symptom score (0–10 points) measures the individual 
symptoms deemed to be most important to each patient at 
baseline.
The AM approach evaluated in this study differs from 
many other therapies used for ADHD in two aspects. 
Whereas in many complementary12,70,71 and conventional 
therapies the child is essentially a passive user of products 
(eg, stimulants, herbs, homeopathic products or nutritional 
products) or recipient of treatments (eg, aromatherapy, 
chiropractic, or massage), the AM approach involves active 
as well as passive therapies. Whereas other active therapies 
(eg, behavioral interventions and neurofeedback) may be 
perceived as monotonous, the AM exercise therapies used 
by three-quarters of patients in this study allow for artistic 
movements (eurythmy) or expression (art therapy). This 
aspect of AM may be especially welcome in children with 
ADHD symptoms, many of whom are described as particu-
larly artistic.42,72
Future studies of AM treatment for ADHD symptoms 
should include a more detailed documentation of the AM 
therapy modalities (eg, for eurythmy therapy, the type of 
exercises used and the frequency and duration of home exer-
cises). Studies with concurrent control groups would be desir-
able. However, it is difficult to conduct randomized trials in 
AM settings, because randomization is often rejected by AM 
physicians and their patients, chiefly due to strong therapy 
preferences.34,35 One possible solution could be to perform a 
pragmatic randomized trial, recruiting patients from outside 
AM settings and randomizing them to immediate treatment International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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in an AM setting or to a waiting-list control group.73 Another 
possibility would be a nonrandomized system comparison of 
treatment by AM and conventional physicians with adjust-
ment for baseline differences.74 In addition, there is scope 
for future qualitative studies exploring the experiences of 
families with children with ADHD symptoms undergoing 
AM treatment.30
Conclusion
In this study, children with ADHD and ADHD-related condi-
tions who received AM treatment had long-term reduction of 
symptoms and improvement of quality of life. The improve-
ment was similar in children not using central stimulants. 
Although the pre–post design of the present study does not 
allow for conclusions about comparative effectiveness, study 
findings suggest that AM therapies may be useful in the long-
term care of children with ADHD symptoms.
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